CML, A Paradigm Of Malignancy- New Developments In The Treatment Of Haematological Malignancies
Keywords:
MedicineReferences
1. Kantarjian HM, Talpaz M, Gutterman JH. Chronic
myelogenous leukemia — past, present, and future.
Hematol Patho 1988; 2: 91-120.
2. Champlin RE, Golde DW. Chronic myelogenous
leukemia: recent advances. Blood 1985; 65: 1039-
1047.
3. Nowell PC, Hungerford DA. A minute chromosome
in human chronic granulocytic leukaemia. Science
1960; 132: 1497-1498.
4. Stryckmans PA. Current concepts in chronic
myelogenous leukemia. Semin Hematol 1974; 11:
101-27.
5. Kantarjian HM, O’Brien S, Anderlini P, Talpaz M.
Treatment of chronic myelogenous leukemia:
current status and investigational options. Blood
1996; 87: 3069-3081.
6. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte
ON, Baltimore D. The chronic myelogenous
leukemia–specific P210 protein is the product of
the bcr/abl hybrid gene. Science 1986; 233: 212-
214.
7. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones
R. Inhibition of apoptosis by BCR-ABL in chronic
myeloid leukemia. Blood 1994; 83: 2038-44.
8. Senechal K, Sawyers CL. Signal transduction-based
strategies for the treatment of chronic myelogenous
leukemia. Mol Med Today. 1996; 2: 503-9.
9. Skorski T, Kanakaraj P, Nieborowska-Skorska M,
Ratajczak MZ, Wen SC, Zon G, et al.
Phosphatidylinositol-3-kinase activity is regulated
by BCR/ABL and is required for the growth of
Philadelphia chromosome-positive cells. Blood
1995; 86: 726-36.
10. Irvine A. Model Systems in the development of
novel therapeutic strategies for the treatment of
CML. Haematology Association of Ireland
Conference; 2000 March; Dublin, Ireland.
11. Ziaic M. STI571. Haematology Association of
Ireland Conference; 2000 March; Dublin, Ireland.
12. Druker B. Status of BCR-ABL tyrosine kinase
inhibitors in CML. Hematology 1999; 169-171.
myelogenous leukemia — past, present, and future.
Hematol Patho 1988; 2: 91-120.
2. Champlin RE, Golde DW. Chronic myelogenous
leukemia: recent advances. Blood 1985; 65: 1039-
1047.
3. Nowell PC, Hungerford DA. A minute chromosome
in human chronic granulocytic leukaemia. Science
1960; 132: 1497-1498.
4. Stryckmans PA. Current concepts in chronic
myelogenous leukemia. Semin Hematol 1974; 11:
101-27.
5. Kantarjian HM, O’Brien S, Anderlini P, Talpaz M.
Treatment of chronic myelogenous leukemia:
current status and investigational options. Blood
1996; 87: 3069-3081.
6. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte
ON, Baltimore D. The chronic myelogenous
leukemia–specific P210 protein is the product of
the bcr/abl hybrid gene. Science 1986; 233: 212-
214.
7. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones
R. Inhibition of apoptosis by BCR-ABL in chronic
myeloid leukemia. Blood 1994; 83: 2038-44.
8. Senechal K, Sawyers CL. Signal transduction-based
strategies for the treatment of chronic myelogenous
leukemia. Mol Med Today. 1996; 2: 503-9.
9. Skorski T, Kanakaraj P, Nieborowska-Skorska M,
Ratajczak MZ, Wen SC, Zon G, et al.
Phosphatidylinositol-3-kinase activity is regulated
by BCR/ABL and is required for the growth of
Philadelphia chromosome-positive cells. Blood
1995; 86: 726-36.
10. Irvine A. Model Systems in the development of
novel therapeutic strategies for the treatment of
CML. Haematology Association of Ireland
Conference; 2000 March; Dublin, Ireland.
11. Ziaic M. STI571. Haematology Association of
Ireland Conference; 2000 March; Dublin, Ireland.
12. Druker B. Status of BCR-ABL tyrosine kinase
inhibitors in CML. Hematology 1999; 169-171.
Downloads
Published
2000-01-01
How to Cite
Whittaker, E. ., Skeffington, B. ., & McCann, S. . (2000). CML, A Paradigm Of Malignancy- New Developments In The Treatment Of Haematological Malignancies. Trinity Student Medical Journal , 1(1), 22–24. Retrieved from https://ojs.tchpc.tcd.ie/index.php/tsmj/article/view/1621
Issue
Section
Reviews
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
